Loomis, Sayles & Company
TMCI icon

Loomis, Sayles & Company’s Treace Medical Concepts TMCI Stock Holding History

Loomis, Sayles & Company’s Portfolio TMCI Stock Details TMCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,126,583
Closed -$14.8M – 1043
2023
Q3 		$14.8M Sell
1,126,583
-109,331
-9% -$2M 0.03% 279
2023
Q2 		$31.6M Buy
1,235,914
+150,727
+14% +$3.89M 0.05% 181
2023
Q1 		$27.3M Buy
+1,085,187
New +$25.5M 0.05% 193

Other funds holding TMCI

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company's TMCI Position: Q4 2023 in Review

Loomis, Sayles & Company sold out of Treace Medical Concepts (TMCI) in Q4 2023, closing a stake of 1,126,583 shares — an estimated $14.8M sold.

Loomis, Sayles & Company first reported a position in TMCI in Q1 2023 and held it in 3 quarters. The position peaked at $31.6M in Q2 2023. 127 funds tracked by Wall St. Rank hold TMCI as of Q4 2023.

  • Loomis, Sayles & Company reported no remaining Treace Medical Concepts position as of Q4 2023 after selling out during the quarter.
  • Loomis, Sayles & Company sold 1,126,583 Treace Medical Concepts shares in Q4 2023, an estimated $14.8M.
  • Loomis, Sayles & Company first reported a position in Treace Medical Concepts in Q1 2023 and held it in 3 quarters.
  • Loomis, Sayles & Company's Treace Medical Concepts position peaked at $31.6M in Q2 2023.
  • 127 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q4 2023.

Based on Loomis, Sayles & Company's 13F filing for Q4 2023, filed 13 Feb 2024.